Boston Biotech Clinical Research
  • Home
    • SCIO Path to Approval
  • Early Clinical Research
    • Strategy and TPP
    • Translational Medicine and Epigenetics
    • Biologics, Cell and Gene Therapy
    • Real World Evidence
    • Repurposing
  • Orphan Drug Solutions
    • Biomarkers and Surrogate Endpoints
    • Regulatory Affairs FDA and EMA
    • Medical Affairs and Clinical Research
    • Due Diligence
    • Trial Management & Trial Rescue
  • People
    • Senior Advisors
      • Candida Fratazzi
      • Claudio Carini
      • Federico Goodsaid
    • Our Clients
    • Our Collaborators
    • Testimonials
  • Resources
    • BBCR Voice
    • Case Studies
    • Published Studies
    • Conferences & Presentations
    • Job Opportunities
    • Contact Info
Select Page

Rare Disease

Rare Disease

Gene Therapy for Rare Disorders Europe 2019 – October 15th – 17th, London

July 15th, 2019 | Rare Disease

Drug development success hinges on simplifying Clinical Research

May 16th, 2019 | Rare Disease

Strategic Consulting: The convergence revolution to innovate clinical trial process

May 10th, 2019 | Rare Disease

Strategic Consulting – SCIO Process -A New Way for Drug Development

April 30th, 2019 | Rare Disease

Strategic consulting reduces cost and risk of clinical trials

April 2nd, 2019 | Rare Disease

SCIO Helps Early Stage Biotech Company Evaluation

January 24th, 2019 | Rare Disease

Welcome to BBCR’s New Website!

December 7th, 2018 | Rare Disease
Newer posts »

Categories

  • Biomarkers & Surrogate Endpoints
  • Company News
  • Drug Development
  • Due Diligence
  • Early Clinical Development
  • Industry News
  • Medical Affairs and Clinical Research
  • Miscellaneous
  • Orphan Diseases
  • Pre-IND
  • Precision Medicine
  • Rare Disease
  • Real World Evidence
  • Regulatory
  • Regulatory Affairs
  • Strategy and TPP
  • Translation Medicine and Epigenetics
  • Trial Management
  • Trial Rescue

Recent Posts

  • Why Rare Disease Drug Development Requires a Different Clinical Strategy
  • Why do orphan drug launches require specialized strategic planning?
  • BBCR and its consultants are dedicated to advancing innovative and repurposed treatments for orphan diseases, an area where impact is high, but the path is complex.
  • BBCR’s mission is to support domestic and international pharma, biotech, and device companies by nurturing their products’ strengths, while improving efficiency and safety. We specialize in strategy and provide early clinical research services to enable informed, timely decision-making for our clients.
  • BBCR brings deep expertise in early-stage development, including Phase 1 and Phase 2 process and strategy, spanning pre-clinical work through pre-IND. Our early drug development capabilities encompass clinical strategy and planning, including the creation of target product profiles and the design of clinical protocols.

RSS Nasdaq Globe Newswire

  • AMSilk and Ajinomoto Foods Europe Expand Partnership to Enable Industrial-Scale Production of Silk Proteins July 8, 2026
  • [Latest] Global Microfluidic Devices Market Size/Share Worth USD 182.98 Billion by 2035 at a 22.36% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) July 7, 2026
  • The Pharma Mini MBA (Nov 4th - Nov 6th, 2026) July 6, 2026
  • FOXO TECHNOLOGIES INC. CEO SEAMUS LAGAN PROVIDES MID-YEAR UPDATE TO SHAREHOLDERS July 6, 2026
PRIVACY POLICY
  • LinkedIn

©2026 Boston Biotech Clinical Research. All Rights Reserved.   |   Web Design by Nisse Designs